Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

Susanne Sebens

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6582-0083; OpenAlex author ID A5011621128. Sources: OpenAlex.

Their work

Papers
39 (first author 1, last author 22)
Trials
0
Grants
0
Labs led
2
Collaborators
93
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 4 papers · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 3 papers · 2021: 7 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 5 papers

Papers 39

  1. Nestin and SOX2 Maintain self-renewal Abilities of Different Pancreatic Cancer Stem Cell Populations. Last author DOI 10.1007/s12015-025-11006-3↗
  2. Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer. Last author DOI 10.1016/j.biopha.2026.119257↗
  3. Intratumoral microbiome and pancreatic cancer: an enabling hallmark and path to novel treatments? Last author DOI 10.1038/s41416-025-03324-7↗
  4. Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-026-01663-z↗
  5. L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma Last author DOI 10.64898/2026.08.10.743835↗
  6. Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling. Co-author DOI 10.1097/cji.0000000000000572↗
  7. Transmembrane Protease Serine 11B Modulates Lactate Transport Through SLC16A1 in Pancreatic Ductal Adenocarcinoma-A Functional Link to Phenotype Heterogeneity. Co-author DOI 10.3390/ijms26115398↗
  8. Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities. Last author DOI 10.3390/cancers16040686↗
  9. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fimmu.2023.1157397↗
  10. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarci… Last author DOI 10.3389/fonc.2023.1160824↗
  11. Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby P… Co-author DOI 10.3390/antiox12101818↗
  12. Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. Last author DOI 10.3390/cancers14194605↗
  13. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  14. The Microbiome Tumor Axis: How the Microbiome Could Contribute to Clonal Heterogeneity and Disease Outcome in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.740606↗
  15. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. Last author DOI 10.3390/cancers13164235↗
  16. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Last author DOI 10.3390/cancers13194932↗
  17. Insulin Receptor in Pancreatic Cancer-Crown Witness in Cross Examination. Co-author DOI 10.3390/cancers13194988↗
  18. Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Duct… Last author DOI 10.3390/ijms22105086↗
  19. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control. Co-author DOI 10.3390/medsci9030048↗
  20. Plant-derived saccharides and their inhibitory potential on metastasis associated cellular processes of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1016/j.carres.2019.107903↗
  21. Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity. Co-author DOI 10.3389/fimmu.2020.01328↗
  22. Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells †. Co-author DOI 10.3390/cancers12030581↗
  23. Metastasis of pancreatic cancer: An uninflamed liver micromilieu controls cell growth and cancer stem cell properties by oxidative phosphorylation in pancreati… Last author DOI 10.1016/j.canlet.2019.03.039↗
  24. POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.26705↗
  25. The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection. Last author DOI 10.3390/cancers11060745↗
  26. Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelia… Last author DOI 10.1016/j.canlet.2017.12.004↗
  27. Liver metastasis of pancreatic cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells. Last author DOI 10.18632/oncotarget.25884↗
  28. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Last author DOI 10.1080/2162402x.2017.1368603↗
  29. In silico analysis of the transportome in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00249-016-1171-9↗
  30. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. Last author DOI 10.1016/j.pan.2016.07.008↗
  31. CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T ce… Last author DOI 10.1080/2162402x.2014.1000083↗
  32. Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity. Co-author DOI 10.4161/2162402x.2014.988460↗
  33. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Last author DOI 10.1016/j.molonc.2014.03.001↗
  34. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Co-author DOI 10.1038/cddis.2014.417↗
  35. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-13-0675↗
  36. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0094357↗
  37. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased protea… First author DOI 10.1038/onc.2012.493↗
  38. Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: cont… Co-author DOI 10.1186/1476-4598-10-67↗
  39. Emerging therapeutic targets and agents for pancreatic cancer therapy--where are we and where we have to go? Co-author DOI 10.2174/187152011795677418↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christoph Röcken · 18 shared papers, 2014–2026 · strength 2.44
  2. H. Schäfer · 16 shared papers, 2013–2025 · strength 1.70
  3. Anna Maxi Wandmacher · 7 shared papers, 2021–2026 · strength 1.63
  4. Daniela Wesch · 13 shared papers, 2014–2026 · strength 1.40
  5. Tina Daunke · 7 shared papers, 2021–2026 · strength 1.24
  6. Silje Beckinger · 7 shared papers, 2019–2026 · strength 1.20
  7. Lisa-Marie Philipp · 5 shared papers, 2018–2026 · strength 1.16
  8. Anne‐Sophie Mehdorn · 5 shared papers, 2021–2026 · strength 1.00
  9. Sascha Rahn · 8 shared papers, 2018–2023 · strength 0.86
  10. Rüdiger Braun · 3 shared papers, 2026 · strength 0.69
  11. Annika Bräuer · 3 shared papers, 2026 · strength 0.69
  12. Anna Trauzold · 5 shared papers, 2014–2025 · strength 0.65
  13. Jan-Paul Gundlach · 5 shared papers, 2017–2026 · strength 0.62
  14. Steffen Markus Heckl · 4 shared papers, 2021–2023 · strength 0.60
  15. Claudia Geismann · 4 shared papers, 2013–2025 · strength 0.53
  16. Meghna Basu · 2 shared papers, 2021–2026 · strength 0.52
  17. Ole Helm · 7 shared papers, 2014–2020 · strength 0.51
  18. Benjamin Heckelmann · 2 shared papers, 2026 · strength 0.46
  19. Lennart Lenk · 6 shared papers, 2015–2019 · strength 0.40
  20. Hendrike Knaack · 4 shared papers, 2018–2024 · strength 0.40
  21. Hans‐Heinrich Oberg · 6 shared papers, 2014–2020 · strength 0.38
  22. Malte Carstensen · 1 shared paper, 2026 · strength 0.33
  23. Nourhane Ammar · 2 shared papers, 2020–2023 · strength 0.32
  24. Dieter Saur · 4 shared papers, 2017–2021 · strength 0.29
  25. Udo Schumacher · 3 shared papers, 2014–2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.